肝硬化合并肠功能紊乱的临床治疗观察

目的探讨肝硬化合并肠功能紊乱的有效治疗方法。方法将50例肝硬化合并肠功能紊乱患者,随机分成治疗组(26例)与对照组(24例),治疗组在对照组治疗方案的基础上给予口服贝飞达、双迪28d,同时给予心理干预治疗。观察两组治疗前后临床症状及主要的肝功能指标。结果对照组肠道功能改善总有效率70%,治疗组总有效率92%,治疗组疗效优于对照组(P<0.05)。两组患者治疗后主要肝功能指标均明显改善,治疗组治疗后ALT、T-BiL值低于对照组(P<0.05)。结论肝硬化合并肠功能紊乱的患者给予微生态制剂、肠动力药及心理干预治疗可有效改善患者临床症状,并降低肝功能指标。

Clinical Research on Hepatic Cirrhosis with Functional Bowel Disorder

Objective To investigate the relationship between the change in intestinal function and the hepatic cirrhosis.Methods Fifty hepatic cirrhosis patients with functional bowel disorder were divided into two groups, i.e. trial group (n=26) and control group (n=24). The trial group received Beifeida, Shuangdi and psychological intervention for 28 days, in addition to routine therapy that was applied to the control group. Results The effective rate of the trial group was 92%, significantly higher than that (70%) of the control group (P<0.05). Although the main parameters of hepatic function of the two groups were ameliorated after therapy, the levels of ALT and T-BiL were significantly lower in the trial group than in the control group (P<0.05). Conclusion It is indicated that prokinetic drug, microecologics and psychological intervention can sharply decrease ALT, T-BiL and complication when used to treat hepatic cirrhosis patients with functional bowel disorder.